Entvantage is developing a rapid diagnostic test kit to help physician's properly diagnose bacterial sinusitis from the more common viral form of the illness. 80% of patients receive antibiotics for symptoms of sinusitis, far above its reported bacterial infection rate of 10%, which leads to over prescription of antibiotics.
Primary Application Area: Medical Devices
Technology Development Status: Prototype
FIGURES OF MERIT
Value Proposition: The overuse of antibiotics that has led to development of antibiotic resistance is a worldwide medical epidemic that has been recognized by the CDC and WHO. Antibiotic use leads to 20% of emergency room visits for adverse drug events. Sinusitis accounts for almost $9 billion in annual direct and indirect costs to the US annually and accounts for 20% of all antibiotics prescribed. The underlying cause of sinusitis is difficult for physicians to diagnose since the symptoms of bacterial and viral sinusitis are very similar and there are no diagnostic tests available for primary care physicians to perform to assist in this diagnosis. This has led to physicians commonly prescribing antibiotics far in excess of its epidemiological occurrence rate. We believe that a point-of-care test will provide physicians with the diagnostic information to reduce the amount of antibiotics unnecessarily prescribed to treat viral sinusitis, improve patient care and help to reduce the amount of antibiotic resistance. The company anticipates that the test kit will sell to the physician clinic for $30 per test and can use existing CPT reimbursement codes to gain reimbursement in excess of $48 per test.
Organization Type: Mid-stage Startup (A or B)
Showcase Booth #: 29T
GOVT/EXTERNAL FUNDING SOURCES
Vetted Programs/Awards: Entvantage was awarded a grant from the Philadelphia Pediatric Medical Device Consortium in September 2015
Entvantage is a member of the University of North Texas Health Science Center Accelerator/Incubator.
Entvantage was awarded the 2015 A-list prize for Top Start-Up by the Austin Chamber of Commerce
SBIR/STTR Awards: None to date
External Funding to Date: Entvantage Diagnostics has received $1.4 million in seed stage investment. The company is currently raising a $3 million Series A funding round.